Abstract
Introduction

Imatinib was the first targeted therapy developed to inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukaemia (CML). The drug has become the first-line treatment for newly diagnosed CML
. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph + leukaemia [6] [7] [8] .
The need for alternative or additional treatment options for imatinib-resistant BCR-ABL positive leukaemia has stimulated the design of a second generation of targeted therapies, which has already resulted in the development of the two novel small-molecule inhibitors nilotinib (AMN107)
, an imatinib mesylate derivative [9] [10] [11] [12] [13] and dasatinib , a combined ABL/SRC kinase inhibitor [14] [15] [16] . [11, [17] [18] [19] . Nilotinib displays a higher binding affinity and selectivity for the ABL kinase than does imatinib. In a recent dose-escalating Phase-I study, imatinib-resistant CML patients in the chronic phase, accelerated phase and blast crisis were treated with nilotinib resulting in cytogenetic and haematological responses of imatinibrefractory CML patients [13] . The [22] [23] [24] [25] [26] , while the effects of nilotinib on normal CD34 + haematopoietic stem cells [27] [28, 29] .
Nilotinib hampers the proliferation and function of CD8
Mixed lymphocyte peptide cultures (MLPCs)
MLPCs were conducted as described earlier [26, [28] [29] [30] [31] [26, 28, 29] .
Measurement of cell proliferation
An indirect 5-bromo-2-deoxyuridine (BrdU)-FITC flow kit (BD
Assessment of apoptosis
Statistical analysis
The results were expressed as the mean ± standard deviation (SD 
effector T cells (data not shown). To confirm that this observation was generally applicable and not limited to the CD8 + T lymphocyte response to IMP, we repeated the experiment with the CMV pp65-derived peptide (Fig. 2, panel B) and the RHAMM-derived R3 peptide (Fig. 2, panel C). We found comparable inhibition of specific CD8 + T lymphocyte expansion in response to these three antigens.
Nilotinib inhibits the IFN-␥ and Gzm-B production of IMP antigen specific CD8 + T cells
To further evaluate the inhibition of functional activation of CD8 + T lymphocytes by nilotinib, ELISPOT assays were performed to assess the production of IFN-␥ and Gzm-B secreted by human IMP specific CD8 + T lymphocytes upon stimulation with autologous CD8 negative APCs which were pulsed with IMP peptide. As shown in representative experiments (Fig. 2, panel D and E), nilotinib reduced the frequency of IFN-␥ (Fig. 2, panel D) and Gzm-B (Fig. 2, panel E) SFCs gradually with increasing concentration of nilotinib. When the concentration of nilotinib was as high as 4 µM, the IFN-␥ and Gzm-B SFCs
Nilotinib reduces levels of phosphorylated Lck, ERK 1/2, ZAP-70 and blocks the NF-B pathway
In (Fig. 4, panel A) and Lck (Fig. 4, panel B) . Moreover, we observed a down-regulation of phospho-NF-B p105 (Ser933) (18E6) (Fig. 4, panel C) , phospho-NF-B2 p100 (Ser864/868) (Fig. 6, panel D) , phospho-ZAP-70 (Fig. 4, panel E (Fig. 4, panel F) , and total IB-␣ (Fig. 4, panel G) , (Fig. 4, panel H) . 
) by nilotinib. Even so, ELISA demonstrated a reduction in phosphorylation of IB-␣ after incubation with nilotinib (Fig. 4, panel G). In contrast, we did not detect down-regulation of other molecules involved in the further T cell signalling cascade ZAP-70
Rel-B, c-Rel, NF-B p105/p50, NF-B2 p100/52, phospho-NF-B p65, (data not shown). For the posphorylated forms of NF-B p105, ERK1/2, ZAP70 and Lck the results were confirmed by western blotting
Comparison of the inhibitory effects on CD8 + T lymphocytes through nilotinib versus imatinib
